-
2 weeks ago | 
nature.com | Jayastu Senapati |Guillermo Garcia-Manero |Courtney DiNardo |Gautam Borthakur |Tapan M Kadia |Elias Jabbour | +8 more
Despite the improvement in overall outcomes of patients with acute myeloid leukemia (AML), some high-risk disease subsets continue to fare dismally. AML with TP53 aberrations (mutations, deletions) is one such subset of high-risk AML with a median survival of about 6–9 months [1,2,3].
-
3 weeks ago | 
nature.com | Mahesh Swaminathan |Courtney DiNardo |Naveen Pemmaraju |Guillermo Garcia-Manero |Ghayas C. Issa |Gautam Borthakur | +9 more
To the Editor:The advent of VEN (VEN) has changed the treatment paradigm of acute myeloid leukemia (AML). Currently, venetoclax (VEN), in combination with a hypomethylating agent (HMA), is approved for the treatment of adult patients with AML unsuitable for intensive chemotherapy or frontline treatment of patients ≥75 years [1].
-
1 month ago | 
nature.com | Courtney DiNardo |Wei-Ying Jen |Koichi Takahashi |Tapan M Kadia |Sanam Loghavi |Patrick K. Reville | +19 more
AbstractIntensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report the long-term experience of 138 patients, 77 ND and 61 RR, treated with FLAG-IDA in combination with venetoclax.
-
Sep 25, 2024 | 
nature.com | Farhad Ravandi |Jayastu Senapati |Nicholas Short |Tapan M Kadia |Gautam Borthakur |Marina Konopleva | +5 more
AbstractOptimal frontline use of active agents in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is prudent to improve outcomes. We report the long-term follow-up of the phase 2 trial of HyperCVAD with nelarabine and pegylated asparaginase (Original cohort). In the latest protocol iteration venetoclax was added to the induction/consolidation regimen (Venetoclax cohort). Eligible patients were adults with untreated T-ALL/LBL or after minimal therapy and with adequate organ function.
-
Sep 19, 2024 | 
nature.com | Courtney DiNardo |Divij Verma |Natalia Baran |Tianyu Cai |Veronica Guerra |Gowri Poigaialwar | +8 more
AbstractMalignancies are reliant on glutamine as an energy source and a facilitator of aberrant DNA methylation. We demonstrate preclinical synergy of telaglenastat (CB-839), a selective glutaminase inhibitor, combined with azacytidine (AZA), followed by a single-arm, open-label, phase 1b/2 study in persons with advanced myelodysplastic syndrome (MDS).
-
Sep 4, 2024 | 
digitalcommons.library.tmc.edu | Alexandre Bazinet |Tapan M Kadia |Nicholas Short |Gautam Borthakur
AbstractAcute myeloid leukemia (AML) can be treated with either high- or low-intensity regimens. Highly sensitive assays for measurable residual disease (MRD) now allow for a more precise assessment of response quality. We hypothesized that treatment (Rx) intensity may not be a key predictor of outcomes, assuming that an optimal response to therapy is achieved.
-
Aug 23, 2024 | 
nature.com | Branko Cuglievan |Hagop Kantarjian |Courtney DiNardo |Tapan M Kadia |Erin Guest |Nicholas Short | +18 more
AbstractAberrant expression of HOX and MEIS1 family genes, as seen in KMT2A-rearranged, NUP98-rearranged, or NPM1-mutated leukemias leads to arrested differentiation and leukemia development. HOX family genes are essential gatekeepers of physiologic hematopoiesis, and their expression is regulated by the interaction between KMT2A and menin.
-
Nov 10, 2023 | 
pericles.pericles-prod.literatumonline.com | Guillermo Montalban-Bravo |Elias Jabbour |Gautam Borthakur |Tapan M Kadia
CONFLICT OF INTEREST STATEMENT G.M.-B. declares grant/research support from Takeda, Rigel and IFM Therapeutics. H.K. declares research support from AbbVie, Agios, Amgen, Ariad, Astex, BMS, Cyclacel, Daiichi-Sankyo, Immunogen, Jazz Pharma, Novartis and Pfizer, honoraria from AbbVie, Actinium, Agios, Amgen, Immunogen, Orsinex, Pfizer and Takeda, and an advisory role with Actinium. G.G.-M.
-
Mar 29, 2023 | 
onclive.com | Gautam Borthakur
Gautam Borthakur, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the ongoing phase 3 SELECT MDS-1 trial (NCT04797780) in patients with newly diagnosed myelodysplastic syndromes (MDS).
